Core Viewpoint - The low-tier market in China is emerging as a new growth area for consumption, with significant demand for baby and nutritional products driven by a high birth rate in these regions [1][19]. Company Overview - Yangtuo Technology Inc, also known as "Haipai Ke," has submitted an IPO application to the Hong Kong Stock Exchange, with CITIC Securities as its sole sponsor [1]. - The company focuses on family care and nutritional products, with over 70% of its revenue coming from the sale of infant formula milk powder in the past three years [1][9]. - Haipai Ke's revenue exceeded 1 billion yuan in 2024, but it faces operational challenges such as declining transaction volume, net profit losses, and decreasing gross margins [1][16]. Financial Performance - Revenue for Haipai Ke was approximately 895 million yuan in 2022, 1.067 billion yuan in 2023, and 1.032 billion yuan in 2024, with net profits showing a downward trend, resulting in losses of 56.54 million yuan in 2023 and 78.83 million yuan in 2024 [16][23]. - The gross margin has decreased from 43.9% in 2022 to 32.5% in 2024, indicating a decline in profitability [16][19]. Market Position - Haipai Ke ranks first in the Chinese family care and nutritional products industry in terms of transaction and service platform, holding a market share of 10.1% in the low-tier market [18][19]. - The overall market size for family care and nutritional products in China is projected to reach 2.6 trillion yuan in 2024, with a compound annual growth rate of 4.9% from 2019 to 2024 [19]. Business Model - The company operates a digital platform that connects manufacturers, distributors, and buyers, allowing registered buyers to place orders directly with upstream sellers [12][13]. - The revenue model is based on commissions from sales transactions on the platform, which has seen a decline in transaction volume from 14.935 billion yuan in 2022 to 10.966 billion yuan in 2024 [23][24]. Competitive Landscape - The family care and nutritional products industry is highly competitive, with major players including Tmall, JD.com, and Pinduoduo, as well as various vertical e-commerce platforms [18][19]. - Despite an increase in registered sellers and buyers, Haipai Ke's transaction volume has decreased, posing challenges for its revenue generation [23][24]. Future Prospects - The company plans to use the funds raised from the IPO to enhance collaboration with ecosystem participants, improve technological capabilities, and explore strategic alliances and investment opportunities [26].

高纯度 Omega-3丨 白皮书 核心摘要： 在健康中国战略全面推进的背景下，国民健康管理意识显著提升，健康需求从 "被动治疗"向"主动预防"加 速转型。随着慢性病防控与亚健康改善成为全民健康的核心议题，膳食营养补充剂已成为全民健康管理的重 要工具，其市场发展与科学认知深化同步推进。基于这一现状，本白皮书旨在深入探讨高纯度 Omega-3 在中国居民健康管理中的作用及应用现状，加强公众对其生理功效的认知，为公众提供更加专业的营养指 导。白皮书从以下五个章节展开： 一、中国居民健康管理现状 国家政策推动全民健康管理向主动预防转型，面对慢性病年轻化与全周期防护挑战，需构建监测、干预与营 养支持体系。膳食营养补充剂通过定向支持和免疫力提升，成为公众践行主动健康管理的核心工具，助力实 现从治疗到预防的跨越。 二、膳食营养补充剂市场认知及应用表现 在国民健康管理需求升级与膳食营养补充剂市场快速发展的双轮驱动下，服用膳食营养补充剂已进阶为现代 人健康管理的核心方案。在消费者决策矩阵中，产品本身与品牌背书构成购买双引擎。但不同人群对成分需 求呈现差异化特征，折射精准健康管理趋势。 三、 Omega-3 产品与应用现状 Om ...

聚焦下沉市场，专注于家庭护理及营养产品领域的交易及服务平台——Yangtuo Technology Inc.（下 称"海拍客"），正式向港股市场进军。智通财经APP获悉，据港交所6月30日披露，海拍客向港交所主 板递交上市申请，中信证券为其独家保荐人。 招股书显示，海拍客成立于2015年。公司通过整合家庭护理及营养产品供应链，为企业客户提供家庭护 理及营养产品组合，优化消费者体验并推动低线市场消费升级。据弗若斯特沙利文的资料，按2024年交 易额计，公司成为中国低线市场家庭护理及营养产品行业为企业提供服务的最大的交易及服务平台，市 场份额为10.1%。 | 排名 | 公司 | 交易额(1) | 市場份額(2) | | --- | --- | --- | --- | | | | (人民幣十億元) | (%) | | | 本集團 | 8.6 | 10.1 | | 2 | 公司A(3) | 5.1 | 5.9 | | 3 | 公司B(4) | 3.5 | 4.1 | | 4 | 公司((5) | 2.6 | 3.0 | | | 公司D(6) | 2.4 | 2.8 | | 小計 | | 22.2 | 25.9 | ...

2015年2月28日，海拍客前身杭州洋驼网络在中国注册成立，并于4月15日转让予现公司董事会主席赵晨先生。 注册成立不久之后，海拍客推出了"海拍客平台(v1.0)"。 值得一提的是，海拍客的核心团队和电商巨头阿里巴巴（09988.HK）关系匪浅。其中，赵晨是海拍客创始人之一，同时也是董事会主席、首席执行官，其 于2006年5月至2015年4月期间在阿里巴巴担任多个职位，其最后职位为高级业务拓展专家，主要负责成立、维护及营运跨境电商平台天猫国际。 得益于核心团队经验丰富，海拍客成立以来发展速度惊人，2016年平台的年度交易额达到10亿元（人民币，下同），到了2019年年度交易额则飙增至100亿 元。 而在发展过程中，海拍客实现了多轮融资，也获得了多家知名机构的青睐，包括顺为资本、高瓴、复星国际等。 自2023年主板上市规则新增第18C章以来，晶泰控股（02228.HK）、黑芝麻智能（02533.HK）、越疆（02432.HK）已经通过第18C章登陆了港股市场。 而在近日，来自杭州西湖区的Yangtuo Technology Inc.（以下简称"海拍客"）向港交所递交了招股书，计划通过第18C章登陆主板，中信证券 ...

Summary of Key Points Core Viewpoint - The Hong Kong Stock Exchange (HKEX) saw 11 companies submit applications for listing from June 30 to July 6, with no companies passing the listing hearing during this period. Additionally, 7 companies initiated their public offerings, and 5 new stocks were listed. Group 1: Companies Submitting Applications - Puxiang Health Holdings Limited is a leading provider of integrated medical and elderly care services in North China, ranking second in revenue among its peers and first in revenue growth from 2022 to 2024 [2] - Magnesium Health Technology Co., Ltd. focuses on innovative payment solutions for medical expenses, being the largest provider of innovative health insurance solutions in China by policy count [3] - Yangtuo Technology Inc. operates a trading and service platform for home care and nutrition products, holding a 10.1% market share in the low-tier market [4] - Xiamen Ruiwei Information Technology Co., Ltd. specializes in image intelligent analysis products and solutions, leveraging machine learning and computer vision technologies [5] - Zijin Gold International Limited is a leading global gold mining company, ranking ninth in gold reserves and eleventh in production as of 2024 [6] - EVE Energy Co., Ltd. is a leading lithium battery platform company, ranking first in China for consumer cylindrical battery shipments and second globally for energy storage battery shipments [7] - Zhejiang Yifei Intelligent Technology Co., Ltd. is a leading industrial robotics company in China, focusing on the light industry [8] - ChipMight Semiconductor Technology (Hangzhou) Co., Ltd. is a leading power semiconductor company, ranking second in the global OLED display PMIC market [9] - Beijing Tongrentang Medical Investment Co., Ltd. is the largest non-public Chinese medicine hospital group by outpatient and inpatient visits [11] - Shandong Linglong Tire Co., Ltd. is the largest OE tire manufacturer in China and the third largest globally [12] - Magnesium Holdings Limited is an innovative automotive technology company focused on AI-driven integrated domain control solutions [13] Group 2: Public Offerings and New Listings - Seven companies initiated their public offerings, including Anjii Foods, which had a subscription rate of 44.2 times for its public offering [14][15] - Other companies like Lens Technology and Fortior also initiated their public offerings with significant interest from cornerstone investors [16][19] - Five new stocks were listed, including Yunzhisheng, which saw a closing price increase of 44.59% on its first day [20][21][22][23] Group 3: Market Insights - The Hong Kong Stock Exchange raised over HKD 107 billion in the first half of 2025, with a 20% increase in the Hang Seng Index [24] - The biopharmaceutical sector has seen a resurgence, with 10 companies successfully listing in the first half of 2025, compared to only 12 for the entire previous year [25][26] - The total fundraising amount for the biopharmaceutical sector reached HKD 15.6 billion in the first half of 2025, indicating strong market interest [26][27]

一周IPO动态，覆盖港股、美股、A股。 本文为IPO早知道原创 作者｜C叔 微信公众号｜ipozaozhidao 云知声 港股｜挂牌上市 据IPO早知道消息，云知声智能科技股份有限公司（以下简称"云知声"）于2025年6月30日正式 以"9678"为股票代码在港交所主板挂牌上市，成为"港股AGI第一股"。 作为中国AGI技术的先行者，成立于2012年的云知声在以深度学习模型发布为标志的人工智能自然 语言处理取得突破后不久，即利用自己在交互式AI方面的研发专业知识和自成立以来获得的市场洞 察力，推出首个基于BERT的大语言模型UniCore，作为自己的中心技术平台云知大脑的初始核心算 法模型，并为广泛的垂直行业的客户赋能一系列AI解决方案。 2016年，云知声战略性地开始建立Atlas AI基础设施，其基于云知声的智算集群，高效地为机器学 习任务动态调度强大的算力，同时这也前沿AI模型的开发、优化和商业化提供重要支撑。目前，云 知声的智算集群拥有超过184 PFLOPS的计算能力，以及超过10PB的存储容量。在过去几年 UniCore的演进和优化的基础上，云知声于2023年推出了一个拥有600亿个参数的自有大语 ...

证券研究报告/行业定期报告 本周整体表现承压,新股上市首秀亮眼 北交所周报(6.23-6.28) 2025 年 07 月 04 日 4)大消费:太湖雪(新国货丝绸第一股)、柏星龙(创意包装第一股)、路斯股份 (北交所宠物食品第一股)、康比特(北交所运动营养第一股)、雷神科技(AI+眼 镜应用领先企业); 5)军工信息化:成电光信(军机升级换代驱动公司特种显示与网络总线业务持续增 长）、星图测控(航天测运控稀缺标的,有望持续受益卫星互联网建设) | 增持(维持) 评级: | | 报告摘要 | | --- | --- | --- | | | | 北交所行情概览: | | | | 1)整体行情:截至 2025年6月28日,北证成份股 268个,平均市值 31.39亿元。 | | 分析师:冯胜 | | 本周北证 50 指数涨跌幅 6.84%，收盘 1439.63点；同期沪深 300、创业板指、科创 | | 执业证书编号:S0740519050004 | | 50 涨跌幅分别为 1.95%、5.69%、3.17%。 | | Email: fengsheng@zts.com.cn | | 2）暴道行情:本周Ａ股涨幅前五的 ...

Core Insights - H&H International Holdings reported a mid-single-digit revenue growth for the six months ending June 30, 2025, driven by growth across all business segments, including adult nutrition and care products, infant nutrition and care products, and pet nutrition and care products [1] Group 1: Adult Nutrition and Care Products - The adult nutrition and care products segment experienced a mid-single-digit revenue increase, primarily due to double-digit growth in mainland China and strong performance in other expanding markets [1] - The growth in this segment is attributed to rising consumer demand for beauty, anti-aging, and detox products, as well as the success of innovative product lines such as Swisse Plus+, Little Swisse, Smart Melts, and Swisse Magnesium Glycinate [1] - Swisse maintains a leading position in the overall vitamin, herbal, and mineral supplement market in mainland China, benefiting from its strong e-commerce presence [1] Group 2: Infant Nutrition and Care Products - The infant nutrition and care products segment saw a return to growth with a low single-digit year-on-year increase, driven by high single-digit growth in infant formula sales [2] - The strategy to attract new consumers, particularly through e-commerce and specialty infant stores, has helped expand market share, with Biostime's ultra-premium infant formula market share increasing from 13.0% to 15.8% [2] - During the 618 online shopping festival, the sales volume of the first and second stages of infant formula recorded a 103% increase [2] - However, the infant probiotics and nutritional supplements segment experienced a double-digit year-on-year decline due to reduced foot traffic in pharmacy channels and industry-wide challenges, although online sales in mainland China still showed low single-digit growth [2] Group 3: Pet Nutrition and Care Products - The pet nutrition and care products segment recorded a high single-digit revenue growth compared to the same period last year, benefiting from the increasing trend of premiumization in pet nutrition, pet humanization, and a rising number of pets [3] - The high-margin pet supplements segment continues to achieve steady revenue growth in the low to mid-double digits [3]

Group 1 - The company plans to publicly issue 50.01 million shares, accounting for 12.50% of the total share capital after issuance [1] - The strategic placement plan will participate in the subscription of up to 10% of the public offering scale, which is 5.01 million shares, with a total subscription amount not exceeding 50 million yuan [1] - The company is an international enterprise group specializing in the research, innovation, and industrialization of dietary nutritional supplements [1] Group 2 - The company's net profit attributable to the parent company for the years 2022 to 2024 is projected to be 142 million yuan, 160 million yuan, and 174 million yuan respectively [2] - The company expects a year-on-year revenue growth of approximately 15.03% to 27.36% for the first half of 2025, with net profit growth of about 8.56% to 19.20% [2] - The total planned investment for fundraising is approximately 603 million yuan, allocated to various projects including the construction of a nutritional health raw material production base and the expansion of production lines [2]

Core Viewpoint - The establishment of Peianmei (Zhejiang) Technology Co., Ltd. marks a significant collaboration between a technology company and the local government, aiming to innovate the healthcare service system through advanced technologies like medical models and brain-machine interfaces [1][2]. Group 1: Company Development - Peianmei was founded in September 2024 with a vision to integrate health management into daily life, supported by a diverse group of stakeholders including state-owned enterprises and universities [2][3]. - Within nine months, Peianmei has rapidly advanced in the health technology sector, establishing partnerships with various universities and institutions to develop innovative health solutions [3][4]. Group 2: Strategic Collaborations - Peianmei has formed strategic partnerships with institutions like Northwest A&F University and Yunnan University of Traditional Chinese Medicine to explore areas such as medical nutrition and traditional medicine integration [3][4]. - The company is also collaborating with Shenzen Yintong Health Industry Co., Ltd. and Capital Medical University to innovate in brain-machine interface technologies [4][6]. Group 3: Technological Innovations - Peianmei is developing a comprehensive health ecosystem that spans prevention, diagnosis, treatment, and rehabilitation, including initiatives like the "Health One Card" platform and the "Special Medical Food Research Laboratory" [5][6]. - The company aims to leverage artificial intelligence and big data to enhance healthcare delivery and management, addressing chronic diseases and improving patient outcomes [6][9]. Group 4: Alignment with National Strategy - Peianmei's initiatives align with national strategies such as the "Artificial Intelligence +" action plan, aiming to contribute to the "Healthy China" initiative by transforming health management practices [8][9]. - The company's ultimate goal is to make health management a daily reality for individuals, emphasizing preventive care and data-driven health solutions [9].